Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

ABSTRACT: Viral hepatitis is among the top four causes of mortality globally, causing 1.4 million deaths each year, exceeding tuberculosis, malaria and human immunodeficiency virus. Hepatitis B and C are responsible for 90% of hepatitis deaths, and the remaining 10% are caused by other hepatitis vir...

Full description

Bibliographic Details
Main Authors: Vicente Soriano, Carmen Alvarez, Benson Edagwa, Carmen de Mendoza, Noemí Montoya, Ana Treviño, Howard Gendelman
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:International Journal of Infectious Diseases
Subjects:
Viral hepatitis
Long-acting antivirals
Chemical vaccines
Hepatitis B
Hepatitis C
Hepatitis D
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221008390

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221008390

Similar Items